Электронная медицинская библиотека Румедо.

Зарубежные материалы

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Дата публикации 22.10.2020
Автор: Benjamin M. Scirica, M.D., M.P.H., Deepak L. Bhatt, M.D., M.P.H., Eugene Braunwald, M.D., P. Gabriel Steg, M.D., Jaime Davidson, M.D., Boaz Hirshberg, M.D., Peter Ohman, M.D., Robert Frederich, M.D., Ph.D., Stephen D. Wiviott, M.D., Elaine B. Hoffman, Ph.D., Matthew A. Cavender, M.D., M.P.H., Jacob A. Udell, M.D., M.P.H., Nihar R. Desai, M.D., M.P.H., Ofri Mosenzon, M.D., Darren K. McGuire, M.D., Kausik K. Ray, M.D., Lawrence A. Leiter, M.D., and Itamar Raz, M.D., for the SAVOR-TIMI 53 Steering Committee and Investigators

The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.

Подробнее

841

Зарубежные материалы

Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus Death

Дата публикации 22.10.2020
Автор: Lorien S. Dalrymple, MD, MPH1, Ronit Katz, DPhil 2, Bryan Kestenbaum, MD, MS 3, Michael G. Shlipak, MD, MPH4,5, Mark J. Sarnak, MD, MS 6, Catherine Stehman-Breen, MD, MS 7, Stephen Seliger, MD, MS 8, David Siscovick, MD, MPH3,9, Anne B. Newman, MD, MPH10,11, and Linda Fried, MD, MPH10,11,12

In the United States, approximately one in three adults aged 65 years and older has chronic kidney disease (CKD), defined as an eGFR ...

Подробнее

746

Зарубежные материалы

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

Дата публикации 22.10.2020
Автор: Steven E. Kahn, M.B., Ch.B., Steven M. Haffner, M.D., Mark A. Heise, Ph.D., William H. Herman, M.D., M.P.H., Rury R. Holman, F.R.C.P., Nigel P. Jones, M.A., Barbara G. Kravitz, M.S., John M. Lachin, Sc.D., M. Colleen O’Neill, B.Sc., Bernard Zinman, M.D., F.R.C.P.C., and Giancarlo Viberti, M.D., F.R.C.P., for the ADOPT Study Group *

The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known.

Подробнее

742

Зарубежные материалы

Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial

Дата публикации 22.10.2020
Автор: Richard I. G. Holt, Rebecca Gossage-Worrall, Daniel Hind, Michael J. Bradburn, Paul McCrone, Tiyi Morris, Charlotte Edwardson, Katharine Barnard, Marian E. Carey, Melanie J. Davies, Chris M. Dickens, Yvonne Doherty, Angela Etherington, Paul French, Fiona Gaughran, Kathryn E. Greenwood, Sridevi Kalidindi, Kamlesh Khunti, Richard Laugharne, John Pendlebury, Shanaya Rathod, David Saxon, David Shiers, Najma Siddiqi, Elizabeth A. Swaby, Glenn Waller and Stephen Wright on behalf of the STEPWISE Research Group*

People with schizophrenia die 10–20 years earlier than the general population, with approximately 75% of deaths resulting from physical illness.1 The twofold increased prevalence of overweight and obesity contributes to this excess mortality.2 Some, but not all, studies suggest that dietary

Подробнее

626

Статьи

Алгоритмы специализированной медицинской помощи больным сахарным диабетом (8-й выпуск)

Дата публикации 22.10.2020
Под редакцией: И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова

Данное издание содержит девятый актуализированный выпуск (дополненный) клинических рекомендаций по стандартизации и оптимизации оказания медицинской помощи больным сахарным диабетом во всех регионах России на основе доказательной медицины.

Подробнее

908

Зарубежные материалы

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Дата публикации 22.10.2020
Автор: Bruce Neal, M.B., Ch.B., Ph.D., Vlado Perkovic, M.B., B.S., Ph.D., Kenneth W. Mahaffey, M.D., Dick de Zeeuw, M.D., Ph.D., Greg Fulcher, M.D., Ngozi Erondu, M.D., Ph.D., Wayne Shaw, D.S.L., Gordon Law, Ph.D., Mehul Desai, M.D., and David R. Matthews, D.Phil., B.M., B.Ch., for the CANVAS Program Collaborative Group

Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes.

Подробнее

814

Статьи

Инициация терапии сахарного диабета 2 типа: новые возможности

Дата публикации 22.10.2020
Автор: А.М. Мкртумян, д.м.н., проф.

В настоящее время сахарный диабет (СД) 2 типа является глобальной проблемой здравоохранения – распространенность патологии достигла масштабов эпидемии как в развитых, так и развивающихся странах

Подробнее

740

Зарубежные материалы

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetesd2019

Дата публикации 22.10.2020
Автор: American Diabetes Association

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care.

Подробнее

1112

Зарубежные материалы

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

Дата публикации 22.10.2020
Автор: William B. White, M.D., Christopher P. Cannon, M.D., Simon R. Heller, M.D., Steven E. Nissen, M.D., Richard M. Bergenstal, M.D., George L. Bakris, M.D., Alfonso T. Perez, M.D., Penny R. Fleck, M.B.A., Cyrus R. Mehta, Ph.D., Stuart Kupfer, M.D., Craig Wilson, Ph.D., William C. Cushman, M.D., and Faiez Zannad, M.D., Ph.D., for the EXAMINE Investigators

To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 ...

Подробнее

971

Зарубежные материалы

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Дата публикации 22.10.2020
Автор: Steven P. Marso, M.D., Stephen C. Bain, M.D., Agostino Consoli, M.D., Freddy G. Eliaschewitz, M.D., Esteban Jódar, M.D., Lawrence A. Leiter, M.D., Ildiko Lingvay, M.D., M.P.H., M.S.C.S., Julio Rosenstock, M.D., Jochen Seufert, M.D., Ph.D., Mark L. Warren, M.D., Vincent Woo, M.D., Oluf Hansen, M.Sc., Anders G. Holst, M.D., Ph.D., Jonas Pettersson, M.D., Ph.D., and Tina Vilsbøll, M.D., D.M.Sc., for the SUSTAIN-6 Investigators

Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk. The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-life of approximately 1 week, in type 2 diabetes are unknown.

Подробнее

758

Зарубежные материалы

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

Дата публикации 22.10.2020
Автор: SILVIO E. INZUCCHI, MD1 RICHARD M. BERGENSTAL, MD2 JOHN B. BUSE, MD, PHD3 MICHAELA DIAMANT, MD, PHD4 ELE FERRANNINI, MD5 MICHAEL NAUCK, MD6 ANNE L. PETERS, MD7 APOSTOLOS TSAPAS, MD, PHD8 RICHARD WENDER, MD9 DAVID R. MATTHEWS, MD, DPHIL10,

Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Подробнее

831

Зарубежные материалы

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus

Дата публикации 22.10.2020
Автор: John B. Buse, MD, PhD, Co-chair; Henry N. Ginsberg, MD, FAHA, Co-chair; George L. Bakris, MD, FAHA; Nathaniel G. Clark, MD, MS, RD; Fernando Costa, MD, FAHA; Robert Eckel, MD, FAHA; Vivian Fonseca, MD; Hertzel C. Gerstein, MD, MSc, FRCPC; Scott Grundy, MD, FAHA; Richard W. Nesto, MD, FAHA; Michael P. Pignone, MD, MPH; Jorge Plutzky, MD; Daniel Porte, MD; Rita Redberg, MD, FAHA; Kimberly F. Stitzel, MS, RD; Neil J. Stone, MD, FAHA

Abstract—The American Heart Association (AHA) and the American Diabetes Association (ADA) have each published guidelines for cardiovascular disease prevention: The ADA has issued separate recommendations for each of the cardiovascular risk factors in patients with diabetes, and the AHA has shaped primary and secondary guidelines that extend to patients with diabetes. This statement will attempt to ...

Подробнее

792

Статьи

Карманные рекомендации для врачей по ведению пациентов с сахарным диабетом и ожирением

Дата публикации 22.10.2020
Под редакцией: М.В. Шестаковой, академика РАН, д.м.н., проф., директора Института диабета, заместителя директора ФГБУ «Эндокринологический научный центр» по научной работе.

Специализированное издание, предназначенное для медицинских и фармацевтических работников

Подробнее

692

Зарубежные материалы

Obesity and Diabetic Kidney Disease

Дата публикации 22.10.2020
Автор: Christine Maric-Bilkan, PhD. Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA

The prevalence of obesity (body mass index, BMI ≥ 30 kg/m2) has risen to epidemic proportions and continues to be a major health problem worldwide 1–3. The high prevalence of obesity is closely linked to the increased incidence of a number of chronic diseases, including type 2 diabetes, hypertension and cardiovascular disease 2, 4–8.

Подробнее

1058

Зарубежные материалы

Diabetes with early kidney involvement may shorten life expectancy by 16 years

Дата публикации 22.10.2020
Автор: Chi Pang Wen, Chia Hsuin Chang, Min Kuang Tsai, June Han Lee, Po Jung Lu, Shan Pou Tsai, Christopher Wen, Chien Hua Chen, Chih Wen Kao, Chwen Keng Tsao and Xifeng Wu

This study aimed to identify the excess risks associated with diabetic patients with early kidney involvement (early diabetic kidney disease). The mortality risks of early diabetic kidney disease, defined as diabetes in early stages 1-3 chronic kidney disease (CKD), were assessed from a cohort of 512,700 adults in Taiwan participating in a health surveillance program from 1994-2008. Three related ...

Подробнее

1175

БИБЛИОТЕКА